Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Aytu Biopharma (AYTU) over the last 15 years, with Sep 2025 value amounting to $5.2 million.

  • Aytu Biopharma's Prepaid Assets fell 91.51% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 91.51%. This contributed to the annual value of $5.6 million for FY2025, which is 10.61% up from last year.
  • Per Aytu Biopharma's latest filing, its Prepaid Assets stood at $5.2 million for Q3 2025, which was down 8.58% from $5.6 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Prepaid Assets peaked at $71.1 million during Q2 2023, and registered a low of $5.1 million during Q2 2024.
  • In the last 3 years, Aytu Biopharma's Prepaid Assets had a median value of $7.5 million in 2025 and averaged $22.8 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first soared by 863.78% in 2023, then crashed by 92.83% in 2024.
  • Over the past 5 years, Aytu Biopharma's Prepaid Assets (Quarterly) stood at $11.3 million in 2021, then increased by 6.12% to $12.0 million in 2022, then crashed by 32.40% to $8.1 million in 2023, then surged by 677.95% to $63.1 million in 2024, then crashed by 91.51% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.6 million for Q2 2025, and $7.5 million during Q1 2025.